Pancreatic cancer is a lethal malignancy with poor prognosis，and it is a serious threat to human health. Imaging examination，serum carbohydrate antigen 19⁃9（CA19⁃9）and tissue biopsy have some limitations in the diagnosis and treatment of pancreatic cancer.Circulating tumor DNA（ctDNA）is one of the newly emerging technologies for“liquid biopsy”. It has shown promising clinical application in the precise treatment of pancreatic cancer due to its simple ，non⁃invasive sampling and real⁃time monitoring of cancer burden. In the study ，we reviewed the application of ctDNA in the early diagnosis of pancreatic cancer，disease stratification，prediction of postoperative recurrence，longitudinal monitoring of treatment response，hoping to provide some references for scientific research and clinical practice.